Telix Pharmaceuticals Limited

A huge shoutout to our incredible employees who participated in Prostate Cancer Awareness Month events during September! 💙 In the US, Telix is a proud supporter of the ZERO Prostate Cancer Run/Walks which help to fund critical research and care for men with prostate cancer. Thank you to #TeamTelix, along with their family and friends, for getting behind this important cause. #PCAM #ZEROout

Telix today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET agent, TLX250-CDx in recurrent clear cell renal cell carcinoma (ccRCC) after surgery. The CA-NINE trial, led by Prof Brian Shuch at UCLA, will investigate the diagnostic performance of TLX250-CDx PET/CT in intermediate-to-high risk ccRCC post-surgery to identify the cancer where it has recurred, including metastatic disease. The investigator-initiated trial is one of multiple trials either underway or planned, which may inform future label expansion for TLX250-CDx. To read more visit our website here: https://bit.ly/3XO861z TLX250-CDx has not received a marketing authorisation in any jurisdiction.

As a former U.S. Navy fighter pilot, Michael Crosby had faced many traumatic situations, but nothing could have prepared him for the moment his doctor said the word "cancer.“ Through his own experience, Mike recognized there was a lack of awareness amongst Veterans about their increased risk of prostate cancer and set out to do something about it by establishing a patient advocacy organization called Veterans Prostate Cancer Awareness. During Prostate Cancer Awareness Month, Telix is sitting down with patients, advocates and physicians to shed light on the current unmet needs in prostate cancer. To read more about what Mike and Telix are doing to help patients visit: https://lnkd.in/gWTGbgSN

Telix today announces an agreement to acquire RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. This is aligned to Telix’s investment strategy around vertically integrated supply chain, manufacturing, and distribution, and will enable the delivery of key therapeutic and diagnostic isotopes alongside finished unit doses in relevant markets. Read more on our website here: https://bit.ly/4gvjpnT Closing of the transaction is subject to customary conditions.

Thank you to the Wallonia Export & Investment Agency (AWEX) for recognising Telix with the Foreign Investment Award at this week’s 2024 Wallonia International Business Awards – an event instigated to celebrate companies operating in the Wallonia region of Belgium that have achieved remarkable performance. Telix has a significant manufacturing presence in Belgium, with sites in Seneffe, Herstal and Liège. We thank the Walloon regional government and AWEX for their continued support of Telix and radiopharmaceuticals - innovation which is positively impacting the lives of patients worldwide. Watch Telix’s award video here: https://bit.ly/4e8vbD0

Telix today announces that it has selected Cardinal Health as a commercial distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx) for the imaging of kidney cancer in the United States. Through their extensive nuclear pharmacy network, the relationship with Cardinal Health has been central to the commercial success of Illuccix® and, subject to regulatory approval, we look forward to adding Zircaix® to their U.S. roster. To read the full announcement, visit our website: https://bit.ly/4daNxly

As a prostate cancer survivor and now a patient advocate, Dr Eddie Wright Snr has always been focused on fighting one thing - fear. It’s what he first felt at diagnosis, and what he believes stops many men from getting tested and diagnosed early. Now, through his patient organization, the We Can Win Foundation, he’s on a mission to change men’s mindsets about prostate cancer. During Prostate Cancer Awareness Month, Telix is sitting down with physicians, advocates and patients to shed light on the current unmet needs in prostate cancer. To read more about what Eddie and Telix are doing to help patients visit: https://bit.ly/47nVClA

Published today in The Lancet Oncology, Shuch and colleagues report that Telix’s first-in-class investigational PET agent, Zircaix® (TLX250-CDx), is a “highly accurate, non-invasive imaging modality for the detection and characterisation of ccRCC.” Authors conclude that “As PET–CT imaging with prostate-specific membrane antigen revolutionised the management of prostate cancer, imaging using TLX250-CDx has the potential to change clinical practice in renal cell carcinoma, including staging and monitoring patients at high risk and detection of distant metastasis.” We sat down with the lead-investigator on Telix’s Phase III ZIRCON trial, Prof Brian Shuch MD, and kidney cancer patient and advocate, Liz Leff, to discuss the results and what access to this imaging candidate means to physicians and the patients they treat. To read more, including the full article, visit our website here: https://bit.ly/4ekmq8C TLX250-CDx has not received a marketing authorisation in any jurisdiction. Zircaix brand name is subject to final regulatory approval.

In his 35 years as a practicing urologist, Dr Paul Dato has seen the field transform with improved screening, diagnostics and therapies helping to halve the U.S. prostate cancer death rate. Here Dr. Dato discusses his experience and some of challenges he has faced, the “revolution” of PSMA theranostics, and what the future might hold for men with this disease. During Prostate Cancer Awareness Month, Telix is sitting down with physicians, advocates and patients to shed light on the current unmet needs in prostate cancer. To read more about what Dr. Dato and Telix are doing to help patients visit: https://lnkd.in/gn-ym4vR